文献速递膀胱癌与上尿路尿路上皮癌

高级别上尿路尿路上皮癌对新辅助化疗反应率高

High Response Rates to Neoadjuvant Chemotherapy in High-Grade Upper Tract Urothelial Carcinoma.
PubMed 文献 · Urology · 2019-03-28

该回顾性研究纳入2011至2017年两家机构接受肾输尿管切除术的95例高级别上尿路尿路上皮癌患者,其中61例eGFR>50 mL/min/1.73 m2者被认为适合新辅助化疗,25例(41%)实际接受顺铂为基础的新辅助化疗。新辅助化疗组临床和病理缓解率均为80%(20/25),最终病理≥pT2期疾病比例20%对直接手术组64%(P=.001)。作者认为高级别上尿路尿路上皮癌患者应考虑新辅助化疗。

要点

  • 95例高级别上尿路尿路上皮癌患者中,61例eGFR>50 mL/min/1.73 m2者被认为适合新辅助化疗,25例(41%)接受新辅助化疗。
  • 新辅助化疗组临床缓解率和病理缓解率(<pT2N0)均为80%(20/25)。
  • 最终病理≥pT2期疾病比例新辅助化疗组20%对直接手术组64%(P=.001)。

核心结论

  • 顺铂为基础的新辅助化疗在高级别上尿路尿路上皮癌中显示出高临床和病理缓解率,且未影响根治性手术治疗。
  • 由于肾输尿管切除术显著降低肾功能和术后顺铂为基础化疗的资格,高级别上尿路尿路上皮癌患者应考虑新辅助化疗。

研究设计与样本

  • 回顾性研究,纳入2011至2017年在2家机构接受肾输尿管切除术的高级别上尿路尿路上皮癌患者95例(平均年龄72.3岁,术前平均eGFR 57.0 mL/min/1.73 m2)。
  • eGFR>50 mL/min/1.73 m2的患者被认为适合新辅助化疗,并在肾输尿管切除术之前转诊评估新辅助化疗。

主要发现

  • 95例符合纳入标准的高级别上尿路尿路上皮癌患者中,61例被认为适合新辅助化疗,其中25例(41%)接受了新辅助化疗。
  • 接受新辅助化疗的患者中,80%(20/25)影像学上有临床缓解,80%(20/25)在肾输尿管切除术标本上有病理缓解(<pT2N0疾病)。
  • 最终病理显示,新辅助化疗组仅20%有≥pT2期疾病,而直接手术组为64%(P=.001)。
  • 接受新辅助化疗的患者无进展生存期(P=.051)和总生存期(P=.052)较直接手术患者显著更长。
  • 没有患者因新辅助化疗出现疾病进展或被判定不适合手术。

临床怎么用

  • 作者认为,高级别上尿路尿路上皮癌患者应考虑新辅助化疗。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the impact of cisplatin-based neoadjuvant chemotherapy (NAC) in patients who underwent nephroureterectomy for high-grade (HG) upper tract urothelial carcinoma (UTUC). METHODS: Retrospective review was conducted of patients with HG UTUC from 2011 to 2017 who underwent nephroureterectomy at 2 institutions. Patients with eGFR >50 mL/min/1.73 m2 were considered eligible for NAC and were referred for evaluation of NAC prior to nephroureterectomy. Patient demographics, kidney function, clinical and pathologic response rates, and outcomes were analyzed. RESULTS: Of 95 patients with HG UTUC meeting inclusion criteria (mean age 72.3 years, mean preop eGFR 57.0 mL/min/1.73 m2), 61 patients were considered eligible for NAC with eGFR >50 mL/min/1.73 m2, of which 25 (41%) received NAC. Of the patients who received NAC, 80% (20/25) of the patients had clinical response on imaging and 80% (20/25) had pathologic response (<pT2N0 disease) on nephroureterectomy. On final pathology, only 20% of the NAC group had ≥pT2 disease compared to 64% of patients who proceeded directly to surgery (P = .001). Patients who received NAC had significantly longer progression free survival (P = .051) and overall survival (P = .052) compared to patients who proceeded directly to surgery. No patients progressed or were deemed ineligible for surgery due to NAC. CONCLUSION: Cisplatin-based NAC demonstrated a high clinical and pathologic response rate in patients with HG UTUC without compromising definitive surgical treatment. Since nephroureterectomy significantly reduces kidney function and eligibility for cisplatin-based chemotherapy after surgery, patients with HG UTUC should be considered for NAC.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Meng X, Chao B, Vijay V, et al. High Response Rates to Neoadjuvant Chemotherapy in High-Grade Upper Tract Urothelial Carcinoma. Urology. 2019. PMID: 30930207. doi:10.1016/j.urology.2019.01.058

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。